Clinical trial NCT05990179: Genomic Uniformed-Screening Against Rare Disease In All Newborns
Official title: Genomic Uniformed-Screening Against Rare Disease In All Newborns
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Early Onset Genetic Conditions With Near Complete Penetrance
Keywords: Newborn screening
Genome sequencing
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: Illumina, Inc.
name: GeneDx
name: New York State Department of Health
First posted: 2023-08-14
Enrollment: 100000
Sex: ALL
Minimum age (years): 1
Maximum age (years): 1
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The goal of this study is to learn how genomic sequencing technology can be used to effectively expand the conditions screened on newborn screening. Newborn screening ensures equity and allows all babies to have the same chance at the healthiest life. Families will be invited to have their newborn baby screened for additional conditions beyond what all babies are screened for as part of the newborn screening public health program. Families can choose to be part of the study or choose not to be part of the study and just have the routine newborn screening test. Families will also be able to choose to learn about their baby's risk for conditions that have effective treatments available but are not on the routine newborn screening panel or also learn about conditions for which there is not currently FDA approved medications but for which medications are under development or for which early intervention services or treatment of seizures may improve the child's outcome. Families will be invited to the study shortly after the baby is born and will learn the decision not to participate, and we will interview a subset of parents who agree to be interviewed. Newborns who screen positive will be referred to appropriate providers for care and will be followed through review of electronic medical records and parental follow up via phone, text, postal mail or email.

Detailed description: Newborn screening (NBS) is the process of screening all newborns for select conditions shortly after birth. This process reduces morbidity and mortality by the detection of medically actionable conditions in pre-symptomatic newborns. Approximately 1 in every 180 newborns is diagnosed with a condition through NBS. NBS is a public health service; every infant regardless of health insurance or ability to pay is tested. NBS ensures equity and allows all babies to have the same chance at the healthiest life. Effective NBS requires coordination and collaboration from multiple stakeholders - the parents, the hospital of birth, state department of health lab, the pediatrician, and the specialty referral center.

Conditions included on the NBS must fulfill several criteria: 1) significant clinical benefit for the newborn early in life including treatment administered within the first few years of life, 2) readiness of public health departments to effectively screen for the condition, and 3) feasibility of successful implementation of population screening. In the United States, screening of newborns is under the purview of state public health departments. Each state decides which disorders to screen, and expansions to each state's panel of screened conditions. The federal government also plays a role through the Secretary of Health and Human Services (HHS) Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC). With rapid improvements in screening technology, diagnostic testing, and treatments, conditions not previously screened through NBS are being considered. Expanding NBS through genome-wide sequencing (GS) will be the most flexible and cost-effective way to add to what is currently in use.

Eligibility criteria: Inclusion Criteria:

* Newborns admitted to the well-baby nurseries from the recruiting hospitals
* Newborns born after 33 weeks of gestation
* Newborns whose parents are English, Mandarin, or Spanish speaking

Primary outcomes:
measure: Enrollment Rate (percentage)
timeFrame: From study launch to end of enrollment (up to 5 years)
measure: Successful Sequencing Rate (percentage)
timeFrame: Up to 6 months after the end of enrollment
measure: Screen Positive Rate (percentage)
timeFrame: Up to 6 months after the end of enrollment
measure: True Positive Rate (percentage)
timeFrame: Up to 6 months after the end of enrollment
Secondary outcomes:
measure: Score on Decision Regret Scale
timeFrame: Up to 6 months after the end of enrollment
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Irving Medical Center/NYP
state: New York
Study officials:
affiliation: Boston Children's Hospital
name: Wendy K. Chung, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: